This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Initially, CDLE presents with multiple, red, thickened, palpable patches, 1-2 cm in diameter, on the face, neck, scalp or hands. These later form red, well-demarcated plaques with adherent scaling. A mild pruritus and tenderness can be seen as well (1).

New lesions are commonly associated with sun exposure while the older lesions heal with scarring and pigmentary change. The scarred areas are often pigmented on caucasian skin but loss of pigment is more common in coloured skin. On close examination, telangiectasia and follicular plugging may be seen at the erythematous active edge. Unlike SLE, lesions in the scalp may leave a permanent scarring alopecia (1).

Older lesions may present from erythematous plaques to hyperkeratotic, dark gray plaques with centrally depressed scars (1).

Lesions on the hands and feet may resemble chilblains.

Exacerbation may occur:

  • in skin trauma
  • ultraviolet light exposure
  • during pregnancy
  • during menstrual or premenstrual periods
  • during oral contraceptives use
  • associated with certains drugs (procainamide, hydralazine, methyldopa) (1)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.